Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.

Webinar | May 21, 2026 | Bioprinting & Spheroids for Cancer Therapy Screening

/upload/promotion-website-39-hm7h3y.png

This presentation details the development of sophisticated 3D platforms combining precision 3D bioprinting with spheroid assembly. Developed exclusively from patient-derived primary cells, these models integrate tumor, immune, and healthy components (hepatocytes, fibroblasts) to faithfully replicate the tumor microenvironment.

Given their long-term viability (spanning several months), these platforms serve as cutting-edge predictive screening tools to evaluate the efficacy, penetration, and toxicity of next-generation biotherapies.

Meet the Speaker

Clément MILET

Laboratory and Quality Director, CTIBIOTECH
Head of the 3D Bioprinting Programme

Clément MILET joined CTIBIOTECH in 2017 to lead the 3D bioprinting programme, building on the organisation’s existing capabilities in 3D cell and tissue culture. He has extensive experience in developing technologies related to cancer research, diagnosis and screening.

His previous experience at the Institute of Advanced Biosciences (Grenoble, France) in cell-based chips for RNA screening, and at the Lyon Cancer Research Centre (CRCL, France), has given him a deep understanding of the need for three-dimensional cancer models. At CTIBIOTECH, he has applied this expertise to primary cancerous and skin tissues donated by patients, using 3D bioprinting to create microtumour and skin models.

Since 2020, Clément Milet has been the Laboratory and Quality Director at CTIBiotech, overseeing various research programmes and expanding production capabilities, particularly through 3D printing.

Key Takeaways

Autologous 3D Platforms

Discover how precision 3D bioprinting combined with spheroid assembly — built exclusively from patient-derived primary cells — integrates tumor, immune, and healthy components (hepatocytes, fibroblasts) to faithfully replicate the tumor microenvironment.

Long-Term Viability

Learn how these platforms maintain viability over several months, enabling extended studies that go beyond the limitations of conventional short-term in vitro models.

Predictive Screening for Biotherapies

Understand how these 3D models serve as predictive screening tools to evaluate the efficacy, penetration, and toxicity of next-generation biotherapies in immuno-oncology.